Kathleen A. Havlin

Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm

Harold J. Burstein, Lyndsay N. Harris, P. Kelly Marcom et al. · Journal of Clinical Oncology · 2003 · 345 citations

Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy

Wendy Demark‐Wahnefried, Vera Hárs, MR Conaway et al. · American Journal of Clinical Nutrition · 1997 · 207 citations · Full text

Physical Activity, Oncology, Breast Oncology +11

A phase I trial of taxol given by a 6-hour intravenous infusion.

T.D. Brown, Kathleen A. Havlin, Geoffrey R. Weiss et al. · Journal of Clinical Oncology · 1991 · 182 citations

Pharmaceutical Science, Oncology, Phase Ii Investigation +12

Phase I clinical investigation of amonafide.

Ruben A. Saez, John B. Craig, John G. Kuhn et al. · Journal of Clinical Oncology · 1989 · 43 citations

Hematological Malignancy, Amonafide Plasma, Oncology +15

High-dose cisplatin for locally advanced or metastatic head and neck cancer. A phase ii pilot study

Kathleen A. Havlin, John G. Kuhn, Judith Myers et al. · Cancer · 1989 · 22 citations · Full text